Alnylam Pharmaceuticals (ALNY) vs Ascendis Pharma A/S (ASND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ascendis Pharma A/S (ASND) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 20.1% versus a loss of 67.0%. Over five years, ASND leads with a +75.7% price change compared with -23.7% for ALNY. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $16.58 billion), about 1.2 times the size.
On valuation, Alnylam Pharmaceuticals trades at a lower forward P/E (14.5x vs 20.5x for Ascendis Pharma A/S).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | ASND |
|---|---|---|
| Share price | $143.82 | $252.73 |
| Market cap | $19.26B | $16.58B |
| 1-day change | -2.71% | -1.26% |
| YTD return | -63.83% | +18.52% |
| 1-year return | -67.04% | +20.07% |
| 5-year return | -23.72% | +75.73% |
| P/E ratio (TTM) | 7.26 | 16.62 |
| Forward P/E | 14.51 | 20.47 |
| EPS (TTM) | $19.80 | $15.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | — |
| Revenue growth (YoY) | +65.19% | — |
| Net income (latest FY) | $313.75M | — |
| Gross margin | 81.77% | — |
| Operating margin | 13.51% | — |
| Net margin | 8.45% | — |
| 52-week high | $479.79 | $282.15 |
| 52-week low | $143.40 | $188.08 |
| Distance from 52-week high | -70.02% | -10.43% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +101.10% | +24.95% |
| Average volume | 2.09M | 750.65K |
| Shares outstanding | 133.94M | 65.60M |
| Employees | 2,500 | 1,189 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASND has outperformed ALNY by 87.1 percentage points over the past year.
- Ascendis Pharma A/S trades at a higher earnings multiple (16.6x vs 7.3x trailing P/E).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About Ascendis Pharma A/S
ASND stock →Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,189 employees
ALNY vs ASND FAQ
Which is bigger, Alnylam Pharmaceuticals or Ascendis Pharma A/S?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $16.58B for Ascendis Pharma A/S (ASND).
Which stock has performed better over the past year, ALNY or ASND?
ASND returned +20.07% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ALNY or ASND?
ALNY has the lower trailing P/E at 7.3, versus 16.6 for ASND. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Alnylam Pharmaceuticals and Ascendis Pharma A/S in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.